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Clinicians rely upon the severity of liver fibrosis to segregate patients with wellcompensated nonalcoholic fatty liver disease (NAFLD) into subpopulations at high-versus low-risk for eventual liver-related morbidity and mortality. We compared hepatic gene expression profiles in high-and low-risk NAFLD patients to identify processes that distinguish the two groups and hence might be novel biomarkers or treatment targets. Microarray analysis was used to characterize gene expression in percutaneous liver biopsies from low-risk, "mild" NAFLD patients (fibrosis stage 0-1; n 5 40) and high-risk, "severe" NAFLD patients (fibrosis stage 3-4; n 5 32). Findings were validated in a second, independent cohort and confirmed by real-time polymerase chain reaction and immunohistochemistry (IHC). As a group, patients at risk for bad NAFLD outcomes had significantly worse liver injury and more advanced fibrosis (severe NAFLD) than clinically indistinguishable NAFLD patients with a good prognosis (mild NAFLD). A 64-gene profile reproducibly differentiated severe NAFLD from mild NAFLD, and a 20-gene subset within this profile correlated with NAFLD severity, independent of other factors known to influence NAFLD progression. Multiple genes involved with tissue repair/regeneration and certain metabolism-related genes were induced in severe NAFLD. Ingenuity Pathway Analysis and IHC confirmed deregulation of metabolic and regenerative pathways in severe NAFLD and revealed overlap among the gene expression patterns of severe NAFLD, cardiovascular disease, and cancer. Conclusion: By demonstrating specific metabolic and repair pathways that are differentially activated in livers with severe NAFLD, gene profiling identified novel targets that can be exploited to improve diagnosis and treatment of patients who are at greatest risk for NAFLD-related morbidity and mortality. (HEPATOLOGY 2013; 00:000-000) N onalcoholic fatty liver disease (NAFLD) is one of the most common types of liver disease in the world. Most patients with NAFLD do not develop clinically significant liver disease, but cirrhosis and/or liver cancer emerge in a subset. 1 The molecular mechanisms underlying the heterogeneous outcomes of NAFLD remain unclear, and this knowledge gap has made it challenging to diagnose and treat NAFLD patients before symptomatic cirrhosis or liver cancer ensue. Liver biopsy studies have provided some help by demonstrating that bad liver outcomes are much more likely in fatty livers with coincident hepatocyte injury and liver inflammation (i.e., nonalcoholic steatohepatitis; NASH) than in livers with simple steatosis. 2, 3 However, NASH encompasses a spectrum of liver injury and inflammation, 4 and not all individuals with NASH ultimately develop cirrhosis or liver cancer. 5 Also, although severity of NASH generally correlates with severity of fibrosis, some individuals with advanced fibrosis have relatively little NASH at the time liver tissue is sampled. 6 Moreover, when advanced fibrosis is present, absence of NASH is no longer prognostic. Therefore, whereas a diagnosis of NASH provides some evidence for a worse prognosis than non-NASH NAFLD, it is of relatively limited help in predicting the ultimate outcome of NAFLD in an individual patient. 3, 5 On the other hand, the stage of fibrosis on liver biopsy independently associates with liver-related mortality and generally correlates with the severity of portal hypertension. 7 The latter is an excellent predictor of eventual liverrelated morbidity, liver cancer, and death. 8, 9 Hence, clinicians typically rely upon fibrosis staging to approximate risk for NAFLD-related morbidity and mortality. The need for early, accurate risk stratification, as well as effective risk-appropriate therapies, is particularly pressing in NAFLD because the disease has become epidemic, imposing a potential public health burden. 10 Tissue gene expression profiling has been valuable for developing diagnostic and predictive biomarkers, as well as for targeting therapy, in cancer and other diseases in which tissue biopsies provide the basis for estimating prognosis and guiding treatment recommendations. [11] [12] [13] Therefore, the aim of this study was to use microarray analysis to characterize a liver gene expression profile that reliably differentiated clinically similar, relatively asymptomatic individuals who were at opposite extremes of the risk spectrum for bad NAFLD-related liver outcomes based on their histologic stage of liver fibrosis. This profile was validated in a second, independent cohort and confirmed by quantitative reversetranscription polymerase chain reaction (qRT-PCR) analysis. After adjusting for the effect of known clinical correlates of liver fibrosis, a subset of the differentially expressed genes that independently correlated with NAFLD severity emerged. Pathway analysis and immunohistochemistry (IHC) revealed that certain metabolic and repair-related processes were selectively induced in livers with severe NAFLD. These findings will facilitate the development of novel diagnostic tests and treatments that target the subgroup of "presymptomatic" NAFLD patients who are at greatest risk for bad NAFLD outcomes.
Materials and Methods
Detailed methods for each section are provided in the Supporting Materials.
Patient Selection and Clinical Variables. We conducted a cross-sectional study utilizing prospectively collected data from NAFLD subjects in the Duke University Health System NAFLD Biorepository (Duke University, Durham, NC). This biorepository was approved by our Institutional Review Board and contains frozen liver biopsies and clinical data from NAFLD patients who underwent a diagnostic liver biopsy to grade and stage severity of disease as part of the standard of care. For the present study, NAFLD was defined as (1) presence of >5% hepatic steatosis on liver biopsy and (2) absence of histologic and serologic evidence for other chronic liver disease in a patient with risk factors for metabolic syndrome (MetS). Patients were selected for inclusion based on histologically defined liver fibrosis stage, a key determinant of clinical outcome. 5 Two groups at the extremes of NAFLD formed the discovery cohort: "mild" NAFLD, defined as fibrosis stages 0 or 1 (n 5 53), and thus little probability of developing clinically significant liver disease over the next one to two decades, and "severe" NAFLD, defined as fibrosis stage 3 or 4 (n 5 56) and thus significant likelihood of developing liver-related morbidity and mortality over the same period (i.e., bad NAFLD outcomes). Groups were matched for gender, age (65 years), and body mass index (BMI; kg/m 2 ; 63 points). Frozen liver biopsies and clinical data from a second, independent cohort of patients (n 5 40) with biopsy-proven NAFLD were identified in the same manner to evaluate the predictive performance of the gene profile (validation cohort). Demographic data (i.e., height, weight, BMI, age, gender, race, ethnicity, smoking status, and comorbid illnesses) and laboratory studies (i.e., lipids, glucose, hemoglobin A1c [HbA1c], liver aminotransferases, and measures of liver synthetic function) were obtained within 6 months of liver biopsy in all patients. Rigorous quality-control procedures resulted in final analyses of 72 patients in the discovery cohort and 17 patients in the validation cohort (Supporting Fig. 1 ; Supporting Tables 1-6).
Liver Biopsy and Histopathological Analysis. Biorepository liver samples are remnants from clinically indicated liver biopsies. Samples were snap-frozen in liquid nitrogen and stored at 280 C. The bulk of each liver biopsy had been processed for routine histology. For the present study, liver slides were re-reviewed and scored by a liver pathologist blinded to the clinical and laboratory data. Severity of NAFLD-related injury and fibrosis were graded and scored according to published criteria. 4 RNA Preparation. See the Methods section of the Supporting Materials for a detailed review of RNA preparation procedures.
Microarray Hybridization and Gene Expression Analysis. Microarray hybridization was performed on Affymetrix Human Genome U133 Plus 2.0 GeneChip arrays (Affymetrix Inc., Santa Clara, CA), using MessageAmp Premier (Applied Biosystems, Foster City, CA) for RNA amplification and hybridization. Data are publically available through the National Center for Biotechnology Information (GSE31803). Differential gene expression was determined using limma (R/Bioconductor statistical package).
14 Results were corrected for multiple testing by Benjamini-Hochberg's method to control the false discovery rate at 5%. We built and performed validation of the gene expression profiles associated with severe NAFLD using Support Vector Machines (SVM).
qRT-PCR. TaqMan qRT-PCR was used to validate the differential expression of eight randomly selected genes identified in the gene profile. Using the available remaining total RNA from selected liver biopsy samples, the RT reaction was performed using the HighCapacity cDNA Archive Kit (Applied Biosystems) using random hexamer priming according to the manufacturer's protocol.
Pathway and Functional Enrichment Analysis. We used the Ingenuity Pathways Analysis (IPA; Ingenuity Systems, Inc., Redwood City, CA, www.ingenuity.com) tool to examine biological functions and disease as well as functional relationships between genes and gene networks.
IHC. Formalin-fixed, paraffin-embedded liver biopsy samples from a subset of patients (n 5 24; 13 mild NAFLD and 11 severe NAFLD) were available for IHC staining. The primary antibodies used were Sonic Hedgehog (SHH), glioblastoma 2 (GLI2), keratin 7 (K7), alpha smooth muscle actin (a-SMA), and sex-determining region Y-box 9 (SOX9).
Statistical Analysis. Demographic, laboratory, histologic, and IHC data were compared between groups using t tests or Wilcoxon's rank-sum tests for continuous predictors and chi-squared or Fisher's exact tests for categorical variables. All tests of significance were two-sided with a P value 0.05 considered significant. Multiple logistic regression analysis was used to assess gene associations with severe NAFLD while controlling for HbA1c, BMI, age, and gender (P < 0.0005 considered significant). All analyses were done using R statistical packages (www.r-project.org) or JMP7 statistical software (SAS Institute Inc., Cary, NC).
Results
Patient Characteristics. The 72 patients in the discovery cohort included 40 with mild NAFLD and 32 with severe NAFLD (Table 1) . As others have reported, 15 patients with mild NAFLD had a lower prevalence of diabetes mellitus (DM) than those with severe NAFLD, but did not differ significantly in other components of the MetS, such as obesity, hypertension, or hyperlipidemia, or medication use that might affect NASH. In contrast, histologic characteristics reflecting disease severity differed among severe NAFLD patients and those with mild NAFLD: the severe NAFLD group had significantly more lobular inflammation, portal inflammation, hepatocyte ballooning, and included more patients with a NAFLD Activity Score (NAS) 5. The findings also demonstrate that fibrosis was an excellent predictor of global liver damage at the time of gene expression analysis in the present study. Clinical and histologic characteristics for the 10 mild NAFLD and 7 severe NAFLD patients in the validation cohort were comparable to those of the discovery cohort (Table 1) .
Gene Expression Differs Between Mild and Severe NAFLD. In the discovery cohort, a total of 1,132 genes were significantly differentially expressed in patients with severe versus mild NAFLD. Unsupervised hierarchical clustering analysis of the top 100 differentially expressed probes revealed two distinct groups with minimal overlap (Fig. 1) . No significant differences in gene expression were detected between patients with no fibrosis (n 5 17) and stage 1 fibrosis (n 5 23) using the same methodology. Gene Ontology (GO) analysis demonstrated that the top up-regulated genes in severe NAFLD included genes associated with biological functions, such as such as cell adhesion and migration (THBS2, EFEMP1, and DPT), development and extracellular matrix (ECM) organization (COL1A2, COL4A1, COL3A1, LUM, FBN1, and DKK3), and regulation of development, transcription and signal transduction (IGFBP7, ID4, EPHA3, and PDGFRA). Interestingly, many of the other top upregulated genes were markers of adult liver progenitor cells, such as JAG1, EPCAM, SOX9, PROM1, and SPP1. The top down-regulated genes in severe NAFLD were generally involved in metabolism and included CYP2C19, DHRS2, OAT, MAT1A, GNMT, and DGAT2. Additional differentially expressed genes are shown in Supporting Table 7 .
IPA Identifies Dysregulation of Cancer, Cardiovascular Disease, and Metabolism-Associated Genes in Severe NAFLD. IPA is useful for revealing similarities between a poorly understood disease and other biologic processes that have been better characterized. This approach identified biological processes that were overrepresented among patients with severe NAFLD relative to mild NAFLD. A core IPA of the set of 1,132 differentially expressed genes revealed overlap with several biological processes, with three of the top five identified being cancer, genetic disorders, and cardiovascular disease (CVD) ( Table 2 ). Closer inspection of the cancer category demonstrated overrepresentation of genes associated with liver cancer (P 5 3.49 3 10 24 ) and colorectal carcinoma (P 5 4.03 3 10 21 ), two cancers associated with NAFLD and the MetS. 16, 17 For example, patients in our severe NAFLD cohort exhibited significant down-regulation of certain metabolic genes that IPA identified as having significant correlations with liver cancer and fibrosis, namely, MAT1A, GNMT, and DGAT2. In mouse models, inhibiting these gene products cause steatohepatitis (MAT1A, GNMT, and DGAT2), advanced liver fibrosis (GNMT and DGAT2), and hepatocellular carcinoma (HCC; MAT1A and GNMT).
18-20 CVD pathways were also overrepresented in our severe NAFLD cohort, consistent with the known association between NASH and CVD, 21 and corroborating a recent publication describing increased cardiovascular mortality in NAFLD patients with noninvasive evidence of advanced liver fibrosis. 22 Gene Profile Associated With Severe NAFLD. Using the hepatic gene expression data from the discovery cohort of 72 patients, we identified a 64-gene profile that was reproducibly associated with severe NAFLD (Table 3) . On average, 7% of patients were misclassified in a test set from the discovery cohort using the SVM repeated hold-out method over 1,000 training and testing iterations. This 64-gene profile had a corresponding area under the receiver operating characteristic curve of 0.978 (Supporting Fig. 2 ). All 64 genes in the profile were up-regulated in severe NAFLD, relative to mild NAFLD. As determined by IPA, prominent genes were associated with biological functions such as tissue remodeling/regeneration (COL1A2, COL3A1, COL4A1, and LUM), progenitor cells (EPCAM, JAG1, and SOX9), cancer (AQP1, CD24, EFEMP1, PDGFRA, SRPX, and SOX4), and CVD (DCN, LAMA2, THBS2, and BCL2). qRT-PCR was used to validate the expression of eight randomly selected genes using total liver RNA from 7 patients with mild NAFLD and 7 patients with severe NAFLD from the discovery cohort. In each case, microarray results were confirmed, with all genes showing significantly increased expression in patients with severe NAFLD (Fig. 2) .
Validation of Severe NAFLD Gene Profile. The 64-gene profile was tested in an independent validation cohort consisting of 17 NAFLD patients (10 mild and 7 severe). It predicted disease status in the validation cohort with a misclassification error rate of 17.6% (i.e., accuracy of 82.4%), confirming that the differentially expressed genes reproducibly characterized two distinct subpopulations of NAFLD patients. Clinical parameters (e.g., age, gender, BMI, and DM), 23 blood tests (e.g., aspartate aminotransferase [AST] platelet ratio index; APRI), 24 or combinations of clinical and laboratory variables (e.g., the NAFLD Fibrosis Score) 25 are often used to estimate the severity of liver fibrosis. These approaches were able to rule out F3-F4 fibrosis in our discovery and validation cohorts with high specificity, but demonstrated only limited sensitivity for detecting advanced fibrosis (Supporting Tables 8 and  9 ). Thus, the predictive values of standard noninvasive tools for staging liver fibrosis in our study populations were similar to those reported by others, 24, 25 underscoring the unmet need for more informative noninvasive biomarkers of NAFLD severity.
To identify genes that enhance accurate characterization of severe NAFLD, we used logistic regression to control for known factors associated with NAFLD fibrosis (i.e., age, gender, BMI, and HbA1c) and identified a 20-gene subset of the 64-gene profile that was independently associated with severe NAFLD (P < 0.0005) in the discovery cohort. These 20 genes (Table 3) were then used to build a new SVM model that improved the misclassification rate to 5.9% in the validation cohort. Analysis of these genes again revealed up-regulation of genes associated with cell adhesion and tissue remodeling/regeneration.
IHC Confirms Activation of Pathways That Promote the Ductular Reaction in Severe NAFLD. Closer inspection of the data acquired by our unbiased geneprofiling approaches indicated that severe NAFLD is characterized by increased expression of Hedgehog (HH) target genes that promote the ductular reaction (DR) (e.g., SOX9, SPP1, and JAG1). Because the DR strongly correlates with fibrosis stage in NAFLD, 26 the present results independently corroborate earlier studies that reported a strong correlation between the level of HH pathway activity and fibrosis severity in other NAFLD patients. 27 Therefore, we felt it was critical to assure that the observed changes in liver messenger RNAs were accompanied by changes in expression of the respective proteins in pertinent cell types in the present NAFLD cohort. We used IHC to mark and quantify accumulation of HH ligand-producing cells (expressing SHH), HH-responsive cells (expressing GLI2), myofibroblasts (expressing a-SMA), and progenitors (expressing K7 and SOX9). The number of cells expressing SHH was greater in severe NAFLD ( Fig. 3 ; P < 0.001), compared to mild NAFLD, as were GLI2-and K7-positive cells ( Fig. 3 ; P 5 0.035 and 0.004). Similarly, the number of cells co-expressing GLI2 and SOX9 was greater in severe NAFLD, relative to mild NAFLD, and paralleled the increase in myofibroblastic cells (a-SMA 1 cells; Fig. 3 ; P < 0.001). Thus, the current IHC data support the microarray data, with both confirming that severe NAFLD is characterized by activation of signaling pathways (such as HH) that promote the DR, a repair response that correlates with fibrosis severity (and thus liver outcomes) in NAFLD. 26, 27 Discussion Improving the outcomes of NAFLD has been hampered by poor understanding of the mechanisms that control either its resolution or progression. Insight has been gleaned from careful characterization of histologic parameters that correlate with the severity of liver fibrosis, which, in turn, is used to predict the 
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The data represent the number of genes that are either up-or down-regulated in severe NAFLD, relative to mild NAFLD. Biological functions, canonical pathways, and toxicological functions were assigned to the overall analysis using findings that have been extracted from the scientific literature and stored in the IPA. A Fisher's exact test corrected for multiple testing by Benjamini-Hochberg's method was used to calculate a q-value determining the probability that the function or pathway assigned to the analysis is explained by chance alone. likelihood of NAFLD progression. 1, 4, 5, 25 Liver biopsy findings demonstrate that the extent of liver cell injury is one of the main parameters that differentiate NASH from NAFL. Histology also shows that NASH itself is a heterogeneous disease that is variably associated with fibrosis. 4 These results suggest that therapeutic success might be improved by subclassifying NAFLD/NASH patients into more homogeneous groups that share common factors for disease progression. However, histology alone is unable to reveal biological processes underlying prognostically relevant differences in hepatic morphology. Thus, alternative methodologies are necessary for further development of noninvasive diagnostic tests and optimization of treatments for various NAFLD subgroups.
Encouraged by successes in the field of oncology wherein gene profiling of malignancies has permitted disease subclassification, 12, 13 we used microarray-based approaches to characterize the gene expression profiles of NAFLD livers at opposite extremes of the fibrosis spectrum. We studied tissues acquired by percutaneous liver biopsy of patients referred to us for NAFLD staging because we reasoned that the resultant information might guide development of novel biomarkers and/or treatments Genes are listed according to the percentage they appear in the 1,000 iterations used to generate the gene profile. Genes in bold are also found in the 20-gene profile of severe NAFLD. Abbreviations: EGF, epidermal growth factor; TGF-b, transforming growth factor beta; BMP, bone morphogenetic protein; ATP, adenosine triphosphate. *Percentage appears over 1,000 iterations signifies the percentage that the Affymetrix probe was included in the gene profile of severe non-alcoholic fatty liver disease over 1,000 iterations of SVM model building.
for types of NAFLD patients who are typically referred to practicing hepatologists for management advice. The resultant microarray data generated a comprehensive, unbiased "snap-shot" of the respective gene expression profiles in NAFLD livers with either severe (F3-F4) or mild (F0-F1) fibrosis. Further computational analysis identified subsets of consistently differentially expressed genes, as well as various signaling pathways that are differentially activated (or suppressed), in the two disease states.
Differential expression of various matrix molecules was demonstrated in NAFLD livers with mild and severe NAFLD. Because we used differences in histologic fibrosis stage to categorize our study cohorts, molecular evidence for fibrosis differences validates the utility of the microarray approach for identifying gene expression profiles that are truly discriminatory. Equally important is the fact that the microarray data reveal specific collagen species (e.g., collagen 1a1, 1a2, 3a1, 4a1, 6a3, and 14a1) and other matrix molecules (e.g., fibrillin 1, laminin a2, and fibulin 5) that are being actively generated in severe NAFLD. Matrix characteristics regulate the fates of cells that mediate fibrogenesis and fibrinolyisis, 28 and thus clinical trials are beginning to target specific matrix molecules for modification in an attempt to promote fibrosis regression (e.g., Clinical Trials.gov identifier: NCT01672866). By characterizing matrix molecules that are selectively accumulating in livers with severe NAFLDrelated damage, the microarray data identify novel therapeutic targets. Our gene profiling also demonstrated differential expression of PDGFRA and one of its ligands, PDGFD, in severe versus mild NAFLD. Pharmacologic antagonists of platelet-derived growth factor (PDGF) signaling are currently available, but there are no reports of their use as NAFLD therapies. Based on our microarray findings, it might be reasonable to target PDGF signaling in presymptomatic patients with NAFLD because this pathway is known to be activated during fibrogenesis and in many cancers. 29 Another noteworthy difference between severe and mild NAFLD was the up-regulation of regeneration/ repair-related genes in severe NAFLD. NAFLD outcomes have been correlated with differences in the extent of hepatocyte death. Indeed, serum levels of cytoskeletal proteins that are released by dying hepatocytes (K8/18) are useful biomarkers of fibrosis severity in NASH. 30 Liver cell death triggers regenerative responses that mobilize myofibroblasts and progenitors, cell types that are involved in the DR. 26, 27 The intensity of the DR correlates with the severity of NAFLDrelated fibrosis. 27 However, the mechanisms underlying this association, and why only some individuals with NASH develop a prominent DR, are unclear. By characterizing the gene profiles that occur in livers with severe NAFLD and mild NAFLD, our microarray analysis provides unbiased insight into these issues. Our results demonstrated that direct transcriptional targets of GLI proteins are prominent among the up-regulated genes in severe NAFLD. This is relevant because GLI proteins are downstream effectors of HH, a morphogenic signaling pathway that controls the fates of ductular-type progenitors and myofibroblasts during adult liver regeneration. 31 Three of the HH-target genes that are activated in severe NAFLD (SOX9, SPP1, and Jagged-1) are particularly pertinent to the DR. Both ductular progenitors 32 and myofibroblastic-stellate cells (MF-HSCs) 33 ,34 express SOX9. SOX9 and GLI proteins interact to control the transcription of SPP1 (osteopontin). 33, 35 Osteopontin is expressed by ductular-type progenitors and MF-HSCs in injured livers, and functions as a profibrogenic factor for HSCs. 33, 35, 36 HH also stimulates MF-HSCs to produce Jagged1, 37 a ligand for the Notch pathway that stimulates ductular differentiation of liver progenitors. 37, 38 In mouse models of liver injury and fibrosis, inhibiting SPP1 or blocking HH signaling prevents accumulation of ductular-type progenitors and myofibroblasts (i.e., the DR) and reduces fibrosis. [33] [34] [35] Hence, our microarray findings provide proof-of-concept support for using unbiased gene profiling to identify molecules or pathways that can be targeted to develop new diagnostic tests and therapies for severe NAFLD. This, in turn, justifies further scrutiny of the present microarray data to identify other novel therapeutic and diagnostic targets in NAFLD. For example, genes that control discrete metabolic processes (e.g., bile acid biosynthesis, branched chain amino acid degradation, and glycine/serine/threonine metabolism) were found to be differentially expressed in livers with mild and severe NAFLD, supporting the need for research to determine if and how these processes affect NAFLD progression.
Useful noninvasive biomarkers of liver disease accurately reflect tissue pathology. Because large clinical data sets are typically enriched with individuals with mild NAFLD, serum biomarker development in NAFLD has focused on perfecting blood tests to detect NAFLD in the general population or to differentiate NASH from simple hepatic steatosis in obese populations at high risk for NAFLD. In contrast, our study population was comprised entirely of subjects with biopsy-proven NAFLD who had either very mild fibrosis or histologically advanced fibrosis. This permitted a more focused comparison of hepatic gene expression profiles that distinguish individuals at opposite ends of the spectrum of NAFLD severity. To further refine the specificity of gene expression differences for marking net differences in NAFLD histology, we used logistic regression to control for potential effects of age, gender, BMI, and glycemic control on liver gene expression. This approach minimized other confounding influences that are known to affect NAFLD-related fibrosis (and thus outcomes). A smaller subset of 20 genes that independently correlated with NAFLD severity emerged from our initial 64-gene profile. Subsequent validation studies demonstrated that this 20-gene profile correctly classified NAFLD severity in 94% patients, inspiring confidence that the differentially expressed molecular targets could be useful for developing new noninvasive diagnostic tests for severe NAFLD. Success would facilitate population-based screening to detect individuals with NAFLD who merit more intensive management because they are at high risk for progressive liver disease. Several of the differentially expressed hepatic genes (e.g., C7, CXCL-6, IGFBP7, and THBS2) encode soluble proteins that are not currently being used as diagnostic or prognostic markers in NAFLD, but are easily assayed and hence could be readily tested for this purpose.
Despite its merits, our study had limitations that are important to acknowledge. First, the sample size was small, particularly in the validation cohort, and this may have limited our power to detect real differences in gene expression. Validation in a second larger, independent data set should be performed to assure confidence in these initial results. Second, the crosssectional design of the study precludes use of discrete data points to predict NAFLD progression and therefore cannot prove causality. The fact that a particular gene or pathway is differentially expressed in patients with mild and severe NAFLD simply identifies it as a marker of one or the other state and suggests that it is a plausible therapeutic target. Future studies that manipulate the activity of such target(s) and assess the affect on clinically relevant outcomes will demonstrate which, if any, drive disease progression. Third, we dichotomized our cohort into more extreme histologic phenotypes and eliminated the intermediate level of fibrosis (i.e., F2). This increased our power to discern more-significant, clinically relevant changes in gene expression, because outcomes of intermediate levels of fibrosis are more variable. Future larger studies that include NAFLD patients with F2 fibrosis will be important to further validate our findings.
